Mankind Pharma

Mankind Pharma ROA

The Return on Assets (ROA) of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 6.81 %. In the previous year, Return on Assets (ROA) was 7.17 % — a change of -5.01% (lower).

ROA

6.81 %

YoY

-5.01%

Last updated:

In 2026, Mankind Pharma's return on assets (ROA) was 6.81 %, a -5.01% increase from the 7.17 % ROA in the previous year.

The Mankind Pharma ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
14.07 INR
Jan 1, 2020
20.31 INR
Jan 1, 2021
19.86 INR
Jan 1, 2022
15.67 INR
Jan 1, 2023
13.19 INR
Jan 1, 2024
15.99 INR
Jan 1, 2025
7.17 INR
Jan 1, 2026
6.81 INR
The Mankind Pharma ROA history
YEARROAYoY
6.81 %-5.01%
7.17 %-55.15%
15.99 %+21.19%
13.19 %-15.80%
15.67 %-21.09%
19.86 %-2.23%
20.31 %+44.38%
14.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

ROA Details

Understanding Mankind Pharma's Return on Assets (ROA)

Mankind Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Mankind Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Mankind Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Mankind Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Mankind Pharma stock

Return on Assets (ROA) of Mankind Pharma is 6.81 % in 2026.

Return on Assets (ROA) of Mankind Pharma changed from 7.17 % to 6.81 %, representing a -5.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Mankind Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Mankind Pharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Mankind Pharma